Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Neurobiol Aging ; 33(4): 827.e11-9, 2012 Apr.
Article in English | MEDLINE | ID: mdl-21821316

ABSTRACT

Epidemiological studies suggest that elevated blood pressure (BP) in midlife is associated with increased risk of Alzheimer's disease (AD) in late life. In this preliminary study, we investigated the extent to which BP measurements are related to positron emission tomography (PET) measurements of fibrillar amyloid-beta burden using Pittsburgh Compound-B (PiB) and fluorodeoxyglucose (FDG) PET measures of cerebral metabolic rate for glucose metabolism (CMRgl) in cognitively normal, late middle-aged to older adult apolipoprotein E (APOE) ε4 homozygotes, heterozygotes and noncarriers. PiB PET results revealed that systolic BP (SBP) and pulse pressure (PP) were each positively correlated with cerebral-to-cerebellar PiB distribution volume ratio (DVR) in frontal, temporal, and posterior-cingulate/precuneus regions, whereas no significant positive correlations were found between PiB distribution volume ratios and diastolic BP (DBP). FDG PET results revealed significant inverse correlations between each of the BP measures and lower glucose metabolism in frontal and temporal brain regions. These preliminary findings provide additional evidence that higher BP, likely a reflection of arterial stiffness, during late midlife may be associated with increased risk of presymptomatic AD.


Subject(s)
Amyloid beta-Peptides/metabolism , Blood Pressure/physiology , Brain Mapping , Brain/metabolism , Age Factors , Aged , Aniline Compounds/metabolism , Apolipoprotein E4/genetics , Blood Pressure/genetics , Brain/diagnostic imaging , Female , Fluorodeoxyglucose F18/metabolism , Glucose/metabolism , Humans , Male , Middle Aged , Positron-Emission Tomography , Thiazoles/metabolism
2.
Arch Neurol ; 67(4): 462-8, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20385913

ABSTRACT

OBJECTIVE: To investigate with fluorodeoxyglucose positron emission tomography whether regional reductions in the cerebral metabolic rate for glucose (CMRgl) previously found in cognitively healthy late-middle-aged apolipoprotein E (APOE) epsilon4 carriers extend to members of the Latino Mexican American community. DESIGN: Prospective cohort study. SETTING: Banner Alzheimer's Institute, Phoenix, Arizona. PATIENTS OR OTHER PARTICIPANTS: Eleven APOE epsilon4 carriers and 16 noncarriers from Arizona's Latino community (mean [SD] age, 54.6 [6.4] years) matched for sex, mean age, and educational level and who were predominantly of self-designated Mexican origin. MAIN OUTCOME MEASURE: A brain mapping algorithm was used to compare cross-sectional regional CMRgl in Latino APOE epsilon4 carriers vs noncarriers. RESULTS: Participant groups had similar distributions for age, sex, education, family history of dementia, clinical ratings, and neuropsychological test scores. Latino APOE epsilon4 carriers had lower CMRgl than the noncarriers in the posterior cingulate, precuneus, and parietal regions previously found to be preferentially affected in patients with Alzheimer disease (AD) and cognitively healthy non-Latino APOE epsilon4 carriers. Additionally, the Latino APOE epsilon4 carriers had lower CMRgl in the middle and anterior cingulate cortex, hippocampus, and thalamus. CONCLUSIONS: This study provides support for the relationship between APOE epsilon4 and risk of AD in Latino individuals. It illustrates the role of positron emission tomography as a presymptomatic endophenotype for the assessment of AD risk factors and supports the inclusion of Latino APOE epsilon4 carriers in proof-of-concept studies using fluorodeoxyglucose PET to evaluate promising presymptomatic treatments in cognitively healthy carriers of this common AD susceptibility gene.


Subject(s)
Alzheimer Disease/genetics , Alzheimer Disease/metabolism , Apolipoprotein E4/genetics , Brain Diseases, Metabolic/genetics , Brain Diseases, Metabolic/metabolism , Brain/metabolism , Aged , Alzheimer Disease/diagnostic imaging , Brain/diagnostic imaging , Brain/physiopathology , Brain Diseases, Metabolic/diagnostic imaging , Brain Mapping/methods , Cohort Studies , Cross-Sectional Studies , DNA Mutational Analysis , Female , Fluorodeoxyglucose F18 , Gene Frequency/genetics , Genetic Carrier Screening , Genetic Markers/genetics , Genetic Predisposition to Disease/genetics , Genetic Testing , Genotype , Heterozygote , Hispanic or Latino/genetics , Humans , Male , Middle Aged , Positron-Emission Tomography , Prospective Studies , Risk Factors
3.
Proc Natl Acad Sci U S A ; 106(16): 6820-5, 2009 Apr 21.
Article in English | MEDLINE | ID: mdl-19346482

ABSTRACT

Fibrillar amyloid-beta (Abeta) is found in the brains of many cognitively normal older people. Whether or not this reflects a predisposition to Alzheimer's disease (AD) is unknown. We used Pittsburgh Compound B (PiB) PET to characterize the relationship between fibrillar Abeta burden and this predisposition in cognitively normal older people at 3 mean levels of genetic risk for AD. Dynamic PiB PET scans, the Logan method, statistical parametric mapping, and automatically labeled regions of interest (ROIs) were used to characterize and compare cerebral-to-cerebellar PIB distribution volume ratios, reflecting fibrillar Abeta burden, in 28 cognitively normal persons (mean age, 64 years) with a reported family history of AD and 2 copies, 1 copy, and no copies of the apolipoprotein E (APOE) epsilon4 allele. The 8 epsilon4 homozygotes, 8 heterozygotes, and 12 noncarriers did not differ significantly in terms of age, sex, or cognitive scores. Fibrillar Abeta was significantly associated with APOE epsilon4 carrier status and epsilon4 gene dose in AD-affected mean cortical, frontal, temporal, posterior cingulate-precuneus, parietal, and basal ganglia ROIs, and was highest in an additional homozygote who had recently developed mild cognitive impairment. These findings suggest that fibrillar Abeta burden in cognitively normal older people is associated with APOE epsilon4 gene dose, the major genetic risk factor for AD. Additional studies are needed to track fibrillar Abeta accumulation in persons with different kinds and levels of AD risk; to determine the extent to which fibrillar Abeta, alone or in combination with other biomarkers and risk factors, predicts rates of cognitive decline and conversion to clinical AD; and to establish the role of fibrillar Abeta imaging in primary prevention trials.


Subject(s)
Alzheimer Disease/genetics , Amyloid beta-Peptides/metabolism , Cognition , Genetic Predisposition to Disease , Aged , Apolipoprotein E4/genetics , Brain Mapping , Gene Dosage , Heterozygote , Homozygote , Humans , Magnetic Resonance Imaging , Middle Aged , Neuropsychological Tests
SELECTION OF CITATIONS
SEARCH DETAIL
...